LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
85.49
-0.33 (-0.38%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close85.82
Open86.17
Bid0.00 x 0
Ask0.00 x 0
Day's Range85.32 - 86.28
52 Week Range74.00 - 89.09
Volume5,826,917
Avg. Volume3,280,614
Market Cap89.524B
Beta0.12
PE Ratio (TTM)40.69
EPS (TTM)2.10
Earnings DateJan 31, 2018
Forward Dividend & Yield2.25 (2.62%)
Ex-Dividend Date2018-02-14
1y Target Est92.36
Trade prices are not sourced from all markets
  • Eli Lilly CEO on Drug Pricing and Diabetes Treatment
    Bloomberg Video12 days ago

    Eli Lilly CEO on Drug Pricing and Diabetes Treatment

    Jan.09 -- David Ricks, chairman and chief executive officer at Eli Lilly & Co., discusses pricing pressures, the drug Trulicity, and the company's commitment to diabetes research. He speaks with Erik Schatzker on "Bloomberg Markets" from the JPMorgan Health Care conference in San Francisco.

  • Pharma And Biotech Dividend Stocks That Will Add Value To Your Portfolio
    Simply Wall St.2 days ago

    Pharma And Biotech Dividend Stocks That Will Add Value To Your Portfolio

    Regularly affected by the ever-changing regulatory environment, the pharmaceutical and biotech industry is not one for producing the most stable cash flow. Thus, investors don’t usually associate this industry withRead More...

  • Merck’s & Co.’s Valuation in January 2018
    Market Realist3 days ago

    Merck’s & Co.’s Valuation in January 2018

    Who’s Watching Merck & Co. in January 2018?Merck & Co.’s valuation

  • PR Newswire3 days ago

    Elanco Innovations Named Best Products for 2017

    GREENFIELD, Ind., Jan. 18, 2018 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY), received two of the top honors in both food and companion animal innovation from Animal Pharm, a leading industry publication.  During the 2017 award cycle, Galliprant (grapiprant tablets) was named Animal Pharm's Best Companion Animal Product and Clynav took top honors as best food animal product. Designed to honor achievements within the animal health sector during a calendar year, Animal Pharm's awards are decided by an independent panel of industry experts.

  • PR Newswire3 days ago

    GALLIPRANT® (grapiprant tablets) Named Best Companion Animal Product for 2017

    LEAWOOD, Kan., Jan. 18, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced GALLIPRANT® (grapiprant tablets) was named Animal Pharm's Best Companion Animal Product for 2017. Galliprant was made commercially available to veterinarians in January 2017 through a license and collaboration agreement with Elanco Animal Health, a division of Eli Lilly and Company (LLY). Galliprant provides targeted pain control from the earliest diagnosed stages of canine osteoarthritis and is the first piprant (a prostaglandin receptor antagonist) approved for use in veterinary medicine.

  • Reuters4 days ago

    U.S. Senate committee advances Azar nomination as health secretary

    A U.S. Senate committee on Wednesday voted to move forward the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar's nomination, with all but one Democrat opposing. To receive final confirmation Azar will have to receive a majority vote in the 100-seat Senate, which Republicans control with 51 seats.

  • Reuters4 days ago

    Key U.S. Senate committee advances Azar nomination for HHS secretary

    A key Senate committee on Wednesday voted to advance the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar's nomination with all but one Democrat opposing. To receive final confirmation Azar will have to receive a majority vote in the 100-seat Senate, which Republicans control with 51 seats.

  • TheStreet.com4 days ago

    A Rally in Eli Lilly Could Heal Traders, Investors

    Prices have improved the past eight weeks and now I want to turn up the volume.

  • Is Eli Lilly and Company a Buy in 2018?
    Motley Fool4 days ago

    Is Eli Lilly and Company a Buy in 2018?

    The outlook is complicated for this big pharma stock.

  • Teva Pharmaceutical: Still Focused on New Product Launches
    Market Realist4 days ago

    Teva Pharmaceutical: Still Focused on New Product Launches

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.

  • How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines
    Investor's Business Daily5 days ago

    How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines

    Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.

  • Benzinga5 days ago

    Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade

    The case for buying shares of Eli Lilly and Co (NYSE: LLY ) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes ...

  • Barrons.com5 days ago

    Big Pharma: Merck Zooms, Eli Lilly Lags

    Big pharmaceutical stocks are moving in disparate directions on Tuesday, with Merck (MRK) rising on good news while Eli Lilly (LLY) was falling after a downgrade. Merck is higher after late-stage trial data showed that Keytruda, when used with two chemotherapy drugs, was successful as a first-line treatment for lung cancer. While the blockbuster drug is already approved for use for cancer treatment, including lung cancer, the results were good news, as Merck and other Big Pharma companies are racing to bring new lung-cancer treatment options to market.  As for Eli Lilly, Goldman Sachs' Jami Rubin and her team downgraded the stock from Buy to Neutral, writing that while they are still bullish on the company's long term, they're concerned that the bull thesis is well understood and already reflected in the stock's valuation. Moreover, Rubin argues, the risk to Lilly's diabetes franchise, particularly Trulicity--the company's biggest and fastest growth driver--isn't fully appreciated by the market, and that could cause downside to consensus estimates.

  • GuruFocus.com9 days ago

    Three Diabetes Clinical Trials to Watch in 2018

    Outcomes on these three clinical trials in diabetes this year could change the way the disease is treated going into the next decade.

  • Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod
    Zacks9 days ago

    Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod

    Eli Lilly (LLY) animal health unit Elanco and partner Aratana announce the EU approval of Galliprant for treatment of pain associated with osteoarthritis in dogs.

  • Wall Street Recommendations for Mylan in January 2018
    Market Realist9 days ago

    Wall Street Recommendations for Mylan in January 2018

    Who’s Watching Mylan in January 2018?

  • Elanco Announces Addition of New North America and Global Strategy Senior Executive
    PR Newswire10 days ago

    Elanco Announces Addition of New North America and Global Strategy Senior Executive

    GREENFIELD, Ind., Jan. 11, 2018 /PRNewswire/ -- Today, Elanco Animal Health, a division of Eli Lilly and Company (LLY), named Sarena Lin as senior vice president, North America Operations and Global Strategy, joining Elanco's Leadership Team and reporting to Elanco president, Jeffrey Simmons.

  • How Mylan’s Rest of the World Segment Performed in 3Q17
    Market Realist10 days ago

    How Mylan’s Rest of the World Segment Performed in 3Q17

    Who’s Watching Mylan in January 2018?

  • PR Newswire10 days ago

    Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe

    LEAWOOD, Kan., Jan. 11, 2018 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY) and Aratana Therapeutics, Inc. (PETX), today announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union. Elanco has exclusive rights to develop, manufacture, market and commercialize Galliprant globally, and it co-promotes the product with Aratana in the United States. Founded in 1954, Elanco is a division of Eli Lilly and Company.

  • Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know
    Motley Fool11 days ago

    Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know

    What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.

  • Ignyta’s Drug Pipeline
    Market Realist12 days ago

    Ignyta’s Drug Pipeline

    Ignyta and Its Drug Candidates for 2018

  • Reuters12 days ago

    Health secretary nominee indicates support for Medicaid overhaul

    Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, indicated on Tuesday he supported a Republican bid to overhaul Medicaid and again vowed to tackle high drug prices. Azar appeared before the Senate Finance Committee on Tuesday, which will ultimately decide whether to move his nomination forward. Azar also vowed to uphold Obamacare as long as it remained the law but said that the program needed changes.

  • Trump health pick wary of government drug price negotiations
    Associated Press12 days ago

    Trump health pick wary of government drug price negotiations

    WASHINGTON (AP) — Empowering Medicare to negotiate drug prices could leave patients with reduced access to medications, President Donald Trump's pick for health secretary warned Tuesday.

  • How Was Incyte’s Revenue Stream in 3Q17?
    Market Realist12 days ago

    How Was Incyte’s Revenue Stream in 3Q17?

    As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.